(Q54272356)

English

Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells

scientific article published on April 1, 1992

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1601333

Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells (English)

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

0 references

1 reference

based on heuristic

inferred from title

bone marrow cells

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1601333

13 October 2022

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

1

object named as

K. Bhalla

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1601333

13 October 2022

3

object named as

J. Lutzky

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1601333

13 October 2022

author name string

C. Holladay

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1601333

13 October 2022

A. M. Ibrado

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1601333

13 October 2022

G. Bullock

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1601333

13 October 2022

M. Jasiok

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1601333

13 October 2022

S. Singh

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1601333

13 October 2022

language of work or name

0 references

publication date

1 April 1992

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1601333

full work available at URL

https://api.elsevier.com/content/article/PII:0090825892904874?httpAccept=text/xml

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

https://api.elsevier.com/content/article/PII:0090825892904874?httpAccept=text/plain

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1601333

45

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1601333

1

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1601333

32-39

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1601333

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

2

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma

3

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma

6

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Phase I clinical and pharmacologic study of deoxycytidine

9

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Intraperitoneal cisplatin with systemic thiosulfate protection

10

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions

11

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.

13

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues

18

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

19

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

20

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Expression of glutathione-related enzymes in human bladder cancer cell lines

22

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications

23

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts

27

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine

28

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Human ovarian cancer cell lines resistant to cisplatin, doxorubicin, and L-phenylalanine mustard are sensitive to delta 7-prostaglandin A1 and delta 12-prostaglandin J2.

29

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Purification and characterization of unique glutathione S-transferases from human muscle

31

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy

34

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells.

35

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation

36

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II).

37

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines.

39

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer

43

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Dose intensity analysis of chemotherapy regimens in ovarian carcinoma

44

1 reference

10.1016/0090-8258(92)90487-4

https://api.crossref.org/works/10.1016/0090-8258(92)90487-4

13 October 2022

Identifiers

10.1016/0090-8258(92)90487-4

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1601333

release_6kpby2qzanea5nl2rjqck73lqe

1 reference

https://api.fatcat.wiki/v0/release/6kpby2qzanea5nl2rjqck73lqe

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1601333

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54272356&oldid=1835598264"